贝达喹啉、德拉马尼和氯法齐明在耐多药结核患者中的药代动力学
该前瞻性队列研究在格鲁吉亚第比利斯纳入99例确诊耐药肺结核患者,于用药4-6周后采血,用液相色谱串联质谱法测定贝达喹啉、德拉马尼和氯法齐明的血清浓度并进行非房室分析。结果显示贝达喹啉和氯法齐明的暴露参数与体重强相关,提示应按体重调整剂量。
要点
- 贝达喹啉和氯法齐明的暴露参数与体重强相关,支持按体重给药。
- 贝达喹啉中位Cmin为0.68 mg/L,氯法齐明为0.52 mg/L,德拉马尼为0.17 mg/L。
- 德拉马尼暴露与饮酒相关,贝达喹啉暴露还与性别相关。
核心结论
- 贝达喹啉和氯法齐明的暴露参数与体重强相关,提示需按体重调整剂量。
研究设计与样本
- 在格鲁吉亚第比利斯开展的前瞻性队列研究,纳入99例≥16岁确诊耐药肺结核患者。
- 患者接受贝达喹啉、德拉马尼和/或氯法齐明治疗,用药4-6周后采血。
- 用验证过的液相色谱串联质谱法测血清浓度,行非房室分析并探索暴露参数与协变量的关联。
主要发现
- 贝达喹啉中位Cmin为0.68 mg/L,中位AUC0-24为30.6 mg·h/L。
- 氯法齐明中位Cmin为0.52 mg/L,中位AUC0-24为16.1 mg·h/L。
- 德拉马尼中位Cmin为0.17 mg/L,中位AUC0-12为2.9 mg·h/L。
- 与暴露参数显著相关的协变量包括:贝达喹啉的体重和性别、德拉马尼的饮酒、氯法齐明的体重。
临床怎么用
- 临床使用贝达喹啉和氯法齐明时应考虑按体重调整剂量。
- 对饮酒患者使用德拉马尼时需关注暴露变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacokinetic data are needed for newly implemented anti-tuberculosis drugs to help optimize their use. OBJECTIVES: To help fill existing knowledge gaps, we evaluated the pharmacokinetic parameters of novel and repurposed anti-tuberculosis drugs among patients with drug-resistant pulmonary tuberculosis. METHODS: A prospective cohort study among patients ≥16 years with confirmed pulmonary drug-resistant TB was conducted in Tbilisi, Georgia. Patients receiving bedaquiline, delamanid and/or clofazimine were included. Blood samples were collected 4-6 weeks after drug initiation, and serum concentrations were measured using validated liquid chromatography tandem mass spectrometry assays. A non-compartmental analysis was performed, and the association of exposure parameters with covariates was explored. RESULTS: Among 99 patients, the average age and weight were 40 years and 65 kg, respectively. The median Cmin was 0.68 mg/L for bedaquiline, 0.17 mg/L for delamanid, and 0.52 mg/L for clofazimine. The median AUC0-24 was 30.6 mg·h/L for bedaquiline, 16.1 mg·h/L for clofazimine, and the AUC0-12 was 2.9 mg·h/L for delamanid. Among the significant covariates associated with drug exposure parameters were weight and sex for bedaquiline, alcohol use for delamanid, and weight for clofazimine. CONCLUSIONS: We found a strong association of weight with bedaquiline and clofazimine exposure parameters, suggesting the need for weight-based dosing for those agents.
引用
- Alghamdi WA, Al-Shaer MH, Kipiani M, et al. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother. 2021. PMID: 33378452. doi:10.1093/jac/dkaa550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。